Obiettivo
Carotid artery disease, the primary trigger of ischaemic cerebrovascular events including stroke, causes major morbidity, mortality and healthcare costs worldwide. Still, treatment is based on criteria established in the 90s that do not take into account the molecular evolution we have witnessed since, nor the introduction of new medication, leading to remarkably high unnecessary surgical treatment while missing most patients at risk.
TAXINOMISIS will provide novel disease mechanism-based stratification for carotid artery disease patients to address the needs for stratified and personalised therapeutic interventions in the current era. This will be achieved through (1) the dissection of mechanisms mediating carotid artery disease, and identification of susceptibility and protection factors of plaque erosion and/or rupture using longitudinal cohorts and multi-omics, (2) the definition of distinct disease phenotypes and endotypes, and generation of molecular fingerprints of high versus low-risk states through systems medicine, (3) the development of a multilevel risk prediction model of the symptomatic plaque incorporating new biomarkers and advanced imaging, implemented in a software, to assist patient stratification and clinical decision making, (4) the development of novel pharmacogenomics solutions based on lab-on-a-chip technology to support personalized treatment, (5) the evaluation of the new risk prediction model and lab-on-a-chip device in a prospective observational clinical study, and (6) the assessment of regulatory, cost-effectiveness and ethical issues towards the implementation and commercialization of the programme’s outcomes.
TAXINOMISIS has therefore the potential to rationally change the current state-of-the-art in the stratification of patients with carotid artery disease by reducing unnecessary operations, refining medical treatment and opening up new avenues for therapeutic intervention, while strengthening the European biotechnology sector.
Campo scientifico
- social sciencessociologydemographymortality
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- engineering and technologyother engineering and technologiesmicrotechnologylab on a chip
- medical and health sciencesbasic medicineneurologystroke
- natural sciencesbiological sciencesmolecular biologymolecular evolution
Parole chiave
Programma(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SC1-2017-Two-Stage-RTD
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
45110 Ioannina
Grecia
Mostra sulla mappa
Partecipanti (16)
3584 CX Utrecht
Mostra sulla mappa
81675 Muenchen
Mostra sulla mappa
11000 Belgrade
Mostra sulla mappa
3001 Leuven
Mostra sulla mappa
115 27 Athina
Mostra sulla mappa
OX1 2JD Oxford
Mostra sulla mappa
02150 Espoo
Mostra sulla mappa
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.
33520 Tampere
Mostra sulla mappa
3500 BN Utrecht
Mostra sulla mappa
16132 Genova
Mostra sulla mappa
10561 Athina
Mostra sulla mappa
08036 Barcelona
Mostra sulla mappa
Soggetto giuridico diverso da un subappaltatore che è affiliato o legalmente collegato a un partecipante. Il soggetto svolge le attività secondo le condizioni stabilite nell’accordo di sovvenzione, fornisce beni o servizi per l’azione, ma non ha sottoscritto l’accordo di sovvenzione. Una terza parte rispetta le regole applicabili al suo partecipante correlato ai sensi dell’accordo di sovvenzione per quanto riguarda l’ammissibilità dei costi e il controllo delle spese.
08036 Barcelona
Mostra sulla mappa
34000 Kragujevac
Mostra sulla mappa
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.
Partecipazione conclusa
00144 Roma
Mostra sulla mappa
000 Zurich
Mostra sulla mappa